Filing Flows › Pacira BioSciences (PCRX) › Q2 2025
Pacira BioSciences (PCRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Pacira BioSciences (PCRX) reported revenue of $181M for the second quarter 2025 (Q2 2025), +2% from a year earlier and +7% from the quarter before. Operating margin was 4.7%, net loss $4.8M (2.7% of revenue).
Pacira BioSciences, Q2 2025: revenue $181M (+2% year over year), operating margin 4.7%, net loss $4.8M, operating cash flow $12.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $181M | +7% | +2% |
| Operating profit | $8.5M | +327% | — |
| Net earnings | −$4.8M | -201% | — |
| Operating cash flow | $12.0M | -66% | -77% |
| Free cash flow | $9.3M | -65% | -82% |
What changed
Revenue was $181.1M in Q2 2025, up 2% year over year and up 7% from the previous quarter. EXPAREL was the largest line at 79% of revenue. EXPAREL added $6.1M year over year (up 4%), 197% of the total change. Bupivacaine liposome injectable suspension declined 84%.
Operating profit was $8.5M, a 4.7% margin (down 11.2 points year over year). Operating profit fell $19.7M even though revenue rose $3.1M versus a year earlier, so costs grew faster than sales. Total costs grew 15% against revenue growth of 2%. The fastest-growing cost line was Research & development (+39%). The quarter ended with a net loss of $4.8M, after a profit of $4.8M the previous quarter. Net interest and other expense of $10.4M was the main reason.
Operating cash flow was $12.0M (down 77% year over year). Non-cash charges added back $27.3M of depreciation and amortization and $15.5M of share-based compensation. Working capital and other items used $25.9M. Capital expenditures of $2.7M left free cash flow of $9.3M.
Questions
What was Pacira BioSciences' revenue in the second quarter 2025?
Pacira BioSciences (PCRX) reported revenue of $181M for the second quarter 2025 (Q2 2025), +2% from a year earlier and +7% from the quarter before.
Was Pacira BioSciences profitable in the second quarter 2025?
Operating profit was $8.5M (4.7% of revenue) and net loss $4.8M.
Source: Pacira BioSciences 10-Q on SEC EDGAR.